Aspen Neuroscience and Bambusa are set to join the public markets, extending a busy IPO streak for drug developers. Aspen Neuroscience’s Parkinson’s cell-therapy effort is highlighted as it raises $141 million, while Bambusa secures $169 million for its I&I-focused approach led by former BioNTech leaders. The dual listings highlight continuing investor appetite for platform and modality innovation even as clinical risk remains front and center for cell therapies. IPO proceeds can materially affect how quickly these companies can expand preclinical work, advance trial readiness, and hire across translational functions. For biotech strategists, the read-through is that capital markets are still underwriting differentiation—especially in neurodegeneration and immunology—when companies can articulate clear technical pathways and milestones for near-term de-risking.